Abstract
Introduction Prior research has reported an increased risk of fatality for cancer patients, but most studies investigated the risk by comparing cancer patients to non-cancer patients among COVID-19 infections. Only a few studies have compared the impact of a COVID-19 infection to non-infection with matched cancer patients and types.
Methods & Materials We conducted survival analyses of 4,606 cancer patients with COVID-19 test results from March 16 to October 11, 2020 in UK Biobank and estimated the overall hazard ratio of fatality with and without COVID-19 infection. We also examined the hazard ratios of thirteen specific cancer types with at least 100 patients.
Results COVID-19 resulted in an overall hazard ratio of 7.76 (95% CI: [5.78, 10.40], p<10−10) by studying the survival rate of 4,606 cancer patients for 21-days after the tests. The hazard ratio was shown to vary among cancer type, with over a 10-fold increase in fatality rate (false discovery rate≤0.02) for melanoma, hematologic malignancies, uterine cancer, and kidney cancer using a stratified analysis on each of the cancer types. Although COVID-19 imposed a higher risk for localized cancers compared to distant metastasis ones, those of distant metastasis yielded higher fatality rates due to their multiplicative effects.
Conclusion The results highlight the importance of timely care for localized and hematological cancer patients and the necessity to vaccinate uninfected patients as soon as possible, particularly for the cancer types influenced most by COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study is partially funded by National Cancer Institute (CA023074).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We applied for data access to UK Biobank on December 6, 2017. The University of Arizona signed a Material Transfer Agreement (MTA) for data and/or sample with UK Biobank on February 22, 2018. The application id is 28979, and the PI is Haiquan Li. Per UK Biobank policy, any COVID-19 related research can be done under an existing MTA or an approved project, with no changes or additional fees. On behalf of Application 28979 on April 17, 2020, we registered to access the following data held by UK Biobank: COVID-19 test data, primary care data, hospitalization data, death data, which covers all data used in this study. Ethical approval of the collection of original data of UK Biobank was given by UK National Health Service (NHS) Health Research Authority on May 13, 2016. The research tissue bank title is 'UK Biobank: a large scale prospective epidemiological resource.' The REC reference is 16/NW/0274, and the IRAS project ID is 200778. The IRB covers all projects approved by UK Biobank. University of Arizona Human Subjects Protection Program confirmed that project 28979 did not require a Human Subjects Review on July 5, 2019, due to the usage of de-identified data. The protocol number is 1907756965.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The results will be shared upon request. The original data was from UK Biobank so the access should follow UK Biobank data access application process.
